Newsletter Subscription

Enter Name and Email

11 April 2014 - Adrian is co-Principal Investigator of a grant from the Int. Rett Syndrome Foundation

International Rett Syndrome Foundation to Neurolixis Inc co-founder and Chief Scientific Officer, an early-stage biopharmaceutical company focused on the discovery and development of novel drugs for the treatment of human central nervous system diseases including Rett syndrome and Parkinson's disease. The grant will support work by a team of researchers led by Prof. Julian Paton (PI) and Dr. Ana Abdala at Bristol University, UK, to characterise a novel serotonin 5-HT1A receptor 'biased agonist', NLX-101 (also known as F15599) in transgenic mice modeling Rett syndrome. If the new studies are successful, Neurolixis aims to take NLX-101, into proof-of-concept Phase 2 trials. 

Read the full press announcement:  pdf_symbol.